Cormark lowered shares of Curaleaf (OTCMKTS:CURLF – Free Report) from a moderate buy rating to a hold rating in a report released on Thursday morning,Zacks.com reports.
Separately, Needham & Company LLC reiterated a “buy” rating and set a $6.25 price objective on shares of Curaleaf in a report on Thursday, August 8th.
Get Our Latest Report on CURLF
Curaleaf Trading Down 5.5 %
Curaleaf (OTCMKTS:CURLF – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 13.35% and a negative net margin of 14.82%. The business had revenue of $342.29 million for the quarter, compared to analyst estimates of $344.57 million. Equities research analysts anticipate that Curaleaf will post -0.24 EPS for the current year.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Articles
- Five stocks we like better than Curaleaf
- How to Invest in Insurance Companies: A Guide
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 11/4 – 11/8
- How to Use the MarketBeat Dividend Calculator
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.